We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
In its upcoming report, Thermo Fisher Scientific (TMO - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $5.25 per share, reflecting a decline of 7.7% compared to the same period last year. Revenues are forecasted to be $10.64 billion, representing a year-over-year increase of 0.7%.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Bearing this in mind, let's now explore the average estimates of specific Thermo Fisher metrics that are commonly monitored and projected by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenues- Laboratory Products and Biopharma Services' should arrive at $5.67 billion. The estimate suggests a change of -1% year over year.
The average prediction of analysts places 'Revenues- Specialty Diagnostics' at $1.10 billion. The estimate points to a change of +1.3% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Life Sciences Solutions' of $2.47 billion. The estimate points to a change of +1.7% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Analytical Instruments' will likely reach $1.85 billion. The estimate indicates a year-over-year change of +5.5%.
It is projected by analysts that the 'Geographic Revenues- Customer Location- North America' will reach $5.64 billion. The estimate indicates a change of -0.4% from the prior-year quarter.
Analysts expect 'Geographic Revenues- Customer Location- Asia-Pacific' to come in at $1.94 billion. The estimate indicates a change of +1.4% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenues- Customer Location- Other regions' reaching $359.04 million. The estimate points to a change of +2.6% from the year-ago quarter.
Analysts forecast 'Geographic Revenues- Customer Location- Europe' to reach $2.70 billion. The estimate points to a change of +2.2% from the year-ago quarter.
Shares of Thermo Fisher have demonstrated returns of -3.4% over the past month compared to the Zacks S&P 500 composite's +3.8% change. With a Zacks Rank #3 (Hold), TMO is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher (TMO) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
In its upcoming report, Thermo Fisher Scientific (TMO - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $5.25 per share, reflecting a decline of 7.7% compared to the same period last year. Revenues are forecasted to be $10.64 billion, representing a year-over-year increase of 0.7%.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Bearing this in mind, let's now explore the average estimates of specific Thermo Fisher metrics that are commonly monitored and projected by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenues- Laboratory Products and Biopharma Services' should arrive at $5.67 billion. The estimate suggests a change of -1% year over year.
The average prediction of analysts places 'Revenues- Specialty Diagnostics' at $1.10 billion. The estimate points to a change of +1.3% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Life Sciences Solutions' of $2.47 billion. The estimate points to a change of +1.7% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Analytical Instruments' will likely reach $1.85 billion. The estimate indicates a year-over-year change of +5.5%.
It is projected by analysts that the 'Geographic Revenues- Customer Location- North America' will reach $5.64 billion. The estimate indicates a change of -0.4% from the prior-year quarter.
Analysts expect 'Geographic Revenues- Customer Location- Asia-Pacific' to come in at $1.94 billion. The estimate indicates a change of +1.4% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenues- Customer Location- Other regions' reaching $359.04 million. The estimate points to a change of +2.6% from the year-ago quarter.
Analysts forecast 'Geographic Revenues- Customer Location- Europe' to reach $2.70 billion. The estimate points to a change of +2.2% from the year-ago quarter.
View all Key Company Metrics for Thermo Fisher here>>>
Shares of Thermo Fisher have demonstrated returns of -3.4% over the past month compared to the Zacks S&P 500 composite's +3.8% change. With a Zacks Rank #3 (Hold), TMO is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>